Marginal Zone Lymphoma Clinical Trials in Atlanta, Georgia

4 studies are recruiting for marginal zone lymphoma in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. SynKIR-310 for Relapsed/Refractory B-NHL

   This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Winship Cancer Institute of Emory University, Atlanta, Georgia

   Locations

   5 in total

   Run by

   Verismo Therapeutics

   See if you can join NCT06544265 on ClinicalTrials.gov

2. Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

   This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of cancer cells by blo…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

   Run by

   Emory University

   See if you can join NCT04883437 on ClinicalTrials.gov

3. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Atlanta, Georgia

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

4. Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

   The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has o…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   4 in total

   Run by

   University of Miami

   See if you can join NCT05296070 on ClinicalTrials.gov